Erythromycin Tablet, Delayed Release
NDC Package 52536-183-10

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Erythromycin tablets is a medication used to treat certain eye infections (such as conjunctivitis). This formulation utilizes a tablet, delayed release delivery system. Marketed by Wilshire Pharmaceuticals, this product is identified by NDC 52536-183 and is authorized under FDA application ANDA062298.

Identification & Billing

NDC Package Code
52536-183-10
Package Description
100 TABLET, DELAYED RELEASE in 1 BOTTLE
Product Code
52536-183
11-Digit Billing Format
52536018310
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Erythromycin
Non-Proprietary Name
Erythromycin
Substance Name
Erythromycin
Dosage Form
Tablet, Delayed Release - A solid dosage form which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
ERYTHROMYCIN 333 mg/1
Pharmacologic Class
Usage Information
This medication is used to treat certain eye infections (such as conjunctivitis). It is also used to prevent certain eye infections in newborns. It belongs to a class of drugs known as macrolide antibiotics. Erythromycin works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Regulatory & Marketing

Labeler Name
Wilshire Pharmaceuticals
Product Type
Human Prescription Drug
FDA Application #
ANDA062298
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-22-2019
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (52536-183). Click a package code to view its specific billing and regulatory data.

52536-183-03
30 TABLET, DELAYED RELEASE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 52536-183-10 identifies a specific commercial package of 100 tablet, delayed release in 1 bottle of Erythromycin, a human prescription drug labeled by Wilshire Pharmaceuticals. This tablet, delayed release is formulated for oral use and contains erythromycin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Wilshire Pharmaceuticals on July 22, 2019. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

This medication is used to treat certain eye infections (such as conjunctivitis). It is also used to prevent certain eye infections in newborns. It belongs to a class of drugs known as macrolide antibiotics. Erythromycin works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

How is this Wilshire Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 52536018310. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
52536-183-10
11-Digit CMS (5-4-2)
52536-0183-10

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.